Merck inks $200 million deal for Hengrui's midstage heart disease drug

Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region

Our TB elimination strategy is based on ‘whole of the society’ and ‘whole of the government’ approach: JP Nadda

Nadda noted that TB treatment coverage in India has increased from 59% to 85%

AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China

Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai

J&J to break ground on new biologics facility in North Carolina

New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases

Neuland appoints Parag Deshmukh as SVP – Head of Manufacturing

Prior to joining Neuland, Deshmukh held several key positions at Cipla

Zota Health Care expands Davaindia network to 1,530 stores

The company has also launched its first three 24*7 pharmacy stores via COCO model in Bengaluru

Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions

The new site will increase Syngene's total single-use bioreactor capacity to 50,000L

Entero launches ‘HealthEdge’ programme to empower Retail Chemists

Croda opens advanced lipids manufacturing facility in Pennsylvania

This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’

Anupriya Patel inaugurates India Innovation Summit – Pioneering Solutions to End TB

TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023